News
Crystal Pharmatech | Reflecting on 2025
21 Feb 2026
Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound
Gatifloxacin (also known as AM-1155, CG5501, and BMS-206584) has been established as a fluoroquinoline broad-spectrum antibiotic (Fukuda et al. 1998) (Fig. 10). It was originally discovered by Kyorin ...
CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
CAMBRIDGE, Massachusetts & CRANBURY, New Jersey, February 21, 2024, – CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to prov...
Unlocking the Power of AI in Pharmaceutical Development
Featuring co-speakers: Kevin Bittorf, Ph.D., and Keith Parent
Application of Compaction Simulation Technology in the Development of Oral Solid Dosage Forms
Characterization of powder mechanical properties and systematic study of powder compression are critical for guiding formulation and process development, enabling tableting scale-up across product lif...
AAPS PharmSci 360
Crystal Pharmatech will be at AAPS Booth 3345 to share practical formulation work and approaches that keep early development on track. If you're building data packages for IND or optimizing a clin...
Subscribe to be the first to get the updates!